and infusion of 0.15 microg·kg-1·min-1for 24-48 hours) tirofiban is recommended and is safe and significantly reduces the incidence of ischemic/thrombotic complications of high-risk PCI. Second, inadequate inhibition of platelets presents particularly shortly after administration; it took at least 2 hours before platelet inhibition reached the desired level of 90%–95%.31Because of the inconsistency in assessing the pre-treatment time between the two groups, it was hard for us to list this characteristic in Table 1. So maybe the insufficiency of pre-time treatment in early administration group was another reason; Third, the capacity to inhibit platelet aggregation while using routine dose of tirofiban was weak as compared with abciximab.28Fourth, most of the patients in the included studies received clopidogrel pre-treatment strategy before PCI. So maybe the benefits from PCI and clopidogrel were enough, and the effect from early administration was limited. Finally, the relevant data on the long-term follow-up period were not available from each study. A better outcome may be observed in long-term follow-up.
Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008; 72: 950-957.
De Luca G, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 2005; 150: 557-562.
Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437-444.
Boden WE, Hoekstra J, Miller CD. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. Am J Emerg Med 2008; 26: 212-220.
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-231.
Zhang Q, Qiu JP, Zhang RY, Hu J, Yang ZK, Ding FH, et al. Improved outcomes from transradial over transfemoral access in primary percutaneous coronary intervention for patients with acute ST-segment elevation myocardial infarction and upstream use of tirofiban. Chin Med J 2013; 126: 1063-1068.
van’t Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004; 25: 837-846.
El Khoury C, Dubien PY, Mercier C, Belle L, Debaty G, Capel O, et al. Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study. Arch Cardiovasc Dis 2010; 103: 285-292.
Hsin HT, Wu CF, Liao PC, Lin PC, Chen LY. Upstream tirofiban reduces reperfusion cardiac arrhythmias in patients of acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2011; 146: 292-294.
Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107: 1497-1501.
Emre A, Ucer E, Yesilcimen K, Bilsel T, Oz D, Sayar N, et al. Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology 2006; 106: 264-269.
Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003; 92: 977-980.
Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, et al. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 2008; 19: 271-277.
Xu L, Yang XC, Wang LF, Ge YG, Wang HS, Li WM, et al. Effect of pre-angiography use of tirofiban in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention (in Chinese). Chin J Cardiol 2006; 34: 983-986.
TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-936.
Higgins J GS, eds. Cochrane handbook for systematic reviews of interventions. Oxford, United Kingdom: Cochrane Collaboration 2008.
Busk M, Maeng M, Rasmussen K, Kelbaek H, Thayssen P, Abildgaard U, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J 2008; 29: 1259-1266.
Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003; 145: 47-57.
Zeymer U, Schroder R, Machnig T, Neuhaus KL. Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction. Am Heart J 2003; 146: 686-691.
Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-684.
Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241.
DE Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemost 2011; 9: 2361-2370.
De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart 2008; 94: 1548-1558.
Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292: 362-366.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Col Cardiol 2013; 61: e78-e140.
Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-2238.
Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106: 1470-1476.
Lele M, Sajid M, Wajih N, Stouffer GA. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001; 104: 582-587.
Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, et al. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res 2005; 116: 55-66.
Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91: 334-336.